Milestone Pharmaceuticals Inc.(MIST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MIST Milestone Pharmaceuticals Inc.

Halted 12-12 16:00:00 EST

2.41

-0.54

-18.31%

盘后2.46

+0.05+2.07%

18:06 EST

High3.06	Low1.61	Vol28.14M
Open3.05	D1 Closing2.95	Amplitude49.15%
Mkt Cap205.26M	Tradable Cap189.94M	Total Shares85.17M
T/O63.54M	T/O Rate35.70%	Tradable Shares78.81M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MIST","market":"US","secType":"STK","nameCN":"Milestone Pharmaceuticals Inc.","latestPrice":2.41,"timestamp":1765573200000,"preClose":2.95,"halted":3,"volume":28139776,"hourTrading":{"tag":"盘后","latestPrice":2.46,"preClose":2.41,"latestTime":"18:06 EST","volume":366246,"amount":904186.4671,"timestamp":1765580788644},"delay":0,"floatShares":78814500,"shares":85169344,"eps":-0.784567,"marketStatus":"Halted","change":-0.54,"latestTime":"12-12 16:00:00 EST","open":3.05,"high":3.06,"low":1.61,"amount":63541099.98817281,"amplitude":0.491525,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.784567,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1557374400000,"exchange":"NASDAQ","adjPreClose":2.95,"preHourTrading":{"tag":"盘前","latestPrice":3.04,"preClose":2.95,"latestTime":"09:29 EST","volume":257002,"amount":782355.6709236,"timestamp":1765549794762},"postHourTrading":{"tag":"盘后","latestPrice":2.46,"preClose":2.41,"latestTime":"18:06 EST","volume":366246,"amount":904186.4671,"timestamp":1765580788644},"volumeRatio":6.074395083516417,"optionData":{"bulkOrders":[{"symbol":"MIST","call":false,"expireDate":1766120400000,"strike":"1.0","timestamp":1765561538624,"price":0.1,"volume":2489,"amount":24890,"type":"-"},{"symbol":"MIST","call":true,"expireDate":1766120400000,"strike":"5.0","timestamp":1765569674258,"price":0.22,"volume":1724,"amount":37928,"type":"-"}]},"impliedVol":2.8832,"impliedVolPercentile":0.872},"requestUrl":"/m/hq/s/MIST/tweets","defaultTab":"tweets","newsList":[{"id":"2591068041","title":"FDA Approves Milestone Pharmaceuticals’ CARDAMYST Nasal Spray for PSVT","url":"https://stock-news.laohu8.com/highlight/detail?id=2591068041","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591068041?lang=en_us&edition=fundamental","pubTime":"2025-12-13 09:00","pubTimestamp":1765587622,"startTime":"0","endTime":"0","summary":"Milestone Pharmaceuticals Inc. has received FDA approval for CARDAMYST  nasal spray, marking the first self-administered treatment for adults with paroxysmal supraventricular tachycardia . This is the first FDA-approved treatment for PSVT in over 30 years, offering more than two million Americans a rapid-acting option that can be used outside of healthcare settings. The approval is supported by robust clinical data, including the successful Phase 3 RAPID trial. CARDAMYST is expected to be available in retail pharmacies in the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Milestone Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 13, 2025, and is ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251213:nNDL6wl3Wr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","SG9999014039.USD","BK4585","IE00BKPKM429.USD","LU2095319765.USD","MIST","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","NDAQ","IE00BGHQF748.EUR","BK4007","SG9999014021.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2591434680","title":"Milestone Receives FDA Approval of Cardamyst™ (Etripamil) as First and Only Self-Administered Nasal Spray for Adults With Paroxysmal Supraventricular Tachycardia (Psvt)","url":"https://stock-news.laohu8.com/highlight/detail?id=2591434680","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591434680?lang=en_us&edition=fundamental","pubTime":"2025-12-13 09:00","pubTimestamp":1765587600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251213:nTUA87Z5GM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIST"],"gpt_icon":0},{"id":"2591688297","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:41 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2591688297","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591688297?lang=en_us&edition=fundamental","pubTime":"2025-12-13 00:41","pubTimestamp":1765557682,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:41 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nAQN2LDFOK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIST"],"gpt_icon":0},{"id":"2582375915","title":"Milestone Pharma Q3 net loss widens on commercial expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375915","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375915?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:17","pubTimestamp":1762949820,"startTime":"0","endTime":"0","summary":"Milestone Pharma Q3 net loss widens on commercial expensesOverviewMilestone Q3 2025 reports no revenue, net loss of $11.9 mlnCompany prepares for CARDAMYST launch pending FDA approval in DecemberMiles","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0DG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIST"],"gpt_icon":0},{"id":"2581864998","title":"Milestone Pharmaceuticals Inc  expected to post a loss of 16 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581864998","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581864998?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:11","pubTimestamp":1762524669,"startTime":"0","endTime":"0","summary":"Milestone Pharmaceuticals Inc  expected to post a loss of16cents a share - Earnings Preview Milestone Pharmaceuticals Inc MIST.OQ MIST.O is expected to  show no change in quarterly revenue when it rep","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ1UM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST","BK4007"],"gpt_icon":0},{"id":"2567118357","title":"Analysts Offer Insights on Healthcare Companies: Kala Pharmaceuticals (KALA) and Milestone Pharmaceuticals (MIST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2567118357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567118357?lang=en_us&edition=fundamental","pubTime":"2025-09-15 17:50","pubTimestamp":1757929811,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kala Pharmaceuticals (KALA – Research Report) and Milestone Pharm...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kala-pharmaceuticals-kala-and-milestone-pharmaceuticals-mist-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kala-pharmaceuticals-kala-and-milestone-pharmaceuticals-mist-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KALA","BK4137","MIST","BK4139","BK4007","HCSG"],"gpt_icon":0},{"id":"2566998041","title":"Milestone Pharmaceuticals Initiated at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2566998041","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566998041?lang=en_us&edition=fundamental","pubTime":"2025-09-11 20:07","pubTimestamp":1757592420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MIST/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 11, 2025 08:07 ET (12:07 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST"],"gpt_icon":0},{"id":"2566448964","title":"Milestone Pharmaceuticals, Inc. : Wells Fargo Initiates Coverage With Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2566448964","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566448964?lang=en_us&edition=fundamental","pubTime":"2025-09-11 18:39","pubTimestamp":1757587148,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nAZN4I4NEZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIST"],"gpt_icon":0},{"id":"2566616789","title":"Wells Fargo Initiates Milestone Pharmaceuticals at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2566616789","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566616789?lang=en_us&edition=fundamental","pubTime":"2025-09-11 18:09","pubTimestamp":1757585356,"startTime":"0","endTime":"0","summary":"Wells Fargo Initiates Milestone Pharmaceuticals at Overweight","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MIST"],"gpt_icon":0},{"id":"2558764970","title":"Milestone Pharmaceuticals Q2 EPS $(0.20) Misses $(0.17) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2558764970","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558764970?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:15","pubTimestamp":1754997337,"startTime":"0","endTime":"0","summary":"Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.17) by 15.61 percent. This is a 42.86 percent decrease over losses of $(0.14) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47054665/milestone-pharmaceuticals-q2-eps-0-20-misses-0-17-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST"],"gpt_icon":0},{"id":"2558649447","title":"Milestone Pharmaceuticals Q2 Income From Operations USD -12.531 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2558649447","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558649447?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:05","pubTimestamp":1754996747,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nPLXB638B6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIST","BK4007"],"gpt_icon":0},{"id":"2558649435","title":"Milestone Pharmaceuticals Q2 Basic EPS USD -0.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2558649435","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558649435?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:05","pubTimestamp":1754996747,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nPLXB638B6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIST"],"gpt_icon":0},{"id":"2558649425","title":"Milestone Pharmaceuticals Inc - FDA Accepts Response to Crl for Cardamyst; Pdufa Date Dec 13, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2558649425","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558649425?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:05","pubTimestamp":1754996747,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nPLXB638B6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIST","BK4007"],"gpt_icon":0},{"id":"2558064949","title":"Milestone Pharmaceuticals Inc - Raises Total Gross Proceeds up to $170 Mln in Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2558064949","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558064949?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:05","pubTimestamp":1754996747,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nPLXB638B6:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIST","BK4007"],"gpt_icon":0},{"id":"2558649485","title":"Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2558649485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558649485?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:05","pubTimestamp":1754996747,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nTUA2PJ60N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIST"],"gpt_icon":0},{"id":"2556382351","title":"Milestone Pharmaceuticals Inc  expected to post a loss of 18 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2556382351","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556382351?lang=en_us&edition=fundamental","pubTime":"2025-08-04 21:26","pubTimestamp":1754313965,"startTime":"0","endTime":"0","summary":"Milestone Pharmaceuticals Inc  expected to post a loss of18cents a share - Earnings Preview Milestone Pharmaceuticals Inc MIST.OQ MIST.O is expected to  show no change in quarterly revenue when it rep","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nL8N3TW16I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST"],"gpt_icon":0},{"id":"2550963191","title":"BUZZ-U.S. STOCKS ON THE MOVE-AeroVironment, Civista Bancshares, Meta","url":"https://stock-news.laohu8.com/highlight/detail?id=2550963191","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550963191?lang=en_us&edition=fundamental","pubTime":"2025-07-12 01:46","pubTimestamp":1752256014,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-AeroVironment, Civista Bancshares, MetaEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250711:nL6N3T80GF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1242518931.SGD","IE00B7SZLL34.SGD","EXPD","LU0788109394.HKD","LU1366192091.USD","LU0882574139.USD","CAPR","KTOS","STRK","LU0742534661.SGD","AMC","LU0784385170.HKD","LU1974910355.USD","SG9999015952.SGD","LU2237957811.SGD","BK4008","LNG","LU1548497426.USD","NEM","LU1670710588.SGD","BK4603","LU0444971666.USD","AVAV","LU0320765059.SGD","LU0354030438.USD","LU0498741114.HKD","META","AZZ","CIVB","LU2236285917.USD","RTX","LU0048573561.USD","LU0266512127.USD","LEVI","LU1430597077.USD","PFGC","KLG","BK4595","NET","MIST","LU2361044865.SGD","LU0466842654.USD","KPTI","SG9999017495.SGD"],"gpt_icon":1},{"id":"2550954978","title":"BRIEF-Milestone Pharmaceuticals Announces Pricing Of $52.5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2550954978","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550954978?lang=en_us&edition=fundamental","pubTime":"2025-07-11 22:29","pubTimestamp":1752244150,"startTime":"0","endTime":"0","summary":"BRIEF-Milestone Pharmaceuticals Announces Pricing Of $52.5 Million Public Offering July 11 (Reuters) - Milestone Pharmaceuticals Inc MIST.O:MILESTONE PHARMACEUTICALS ANNOUNCES PRICING OF $52.5 MILLION","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250711:nFWN3T8196:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST","BK4007"],"gpt_icon":0},{"id":"2550689958","title":"BUZZ-U.S. STOCKS ON THE MOVE-Levi Strauss, Crypto Stocks, Delta","url":"https://stock-news.laohu8.com/highlight/detail?id=2550689958","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550689958?lang=en_us&edition=fundamental","pubTime":"2025-07-11 19:39","pubTimestamp":1752233960,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Levi Strauss, Crypto Stocks, DeltaEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"4bacc9bc14bd04f0da4160badf4deb64","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250711:nL6N3T80F9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4500","LU1861559042.SGD","BK4202","LU0757428866.USD","BK4588","STRK","BK4539","MIST","LU0052756011.USD","BK4139","LU1861220207.SGD","BK4516","LU1267930227.SGD","BK4086","BK4023","AZZ","LEVI","LU2360107671.USD","BK4596","CAPR","LU0310800965.SGD","BK4547","BK4600","BK4595","LU0128525689.USD","LU1861558580.USD","DAL","LU1861217088.USD","BK4535","BK4007","IE00BFMHRM44.USD","BK4551","BK4008","BK4585","BK4182","BK4554","LU1815336091.USD","BK4112"],"gpt_icon":1},{"id":"2550937023","title":"Milestone Pharmaceuticals Says FDA Accepted for Review Cardamyst Nasal Spray Resubmission","url":"https://stock-news.laohu8.com/highlight/detail?id=2550937023","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550937023?lang=en_us&edition=fundamental","pubTime":"2025-07-11 19:02","pubTimestamp":1752231741,"startTime":"0","endTime":"0","summary":"Milestone Pharmaceuticals  said Friday the US Food and Drug Administration has accepted for review its response to issues raised in the regulator's complete response letter for Cardamyst nasal spray.The FDA has set a target action date of Dec. 13.Cardamyst nasal spray is a novel investigational therapy for the treatment of acute episodes of paroxysmal supraventricular tachycardia, a type of abnormal heart rhythm.Shares of the company were down ore than 24% in Friday premarket activity.Price: 1.94, Change: -0.62, Percent Change: -24.22","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MIST","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.milestonepharma.com","stockEarnings":[{"period":"1week","weight":-0.1007},{"period":"1month","weight":0.2487},{"period":"3month","weight":0.2296},{"period":"6month","weight":0.4606},{"period":"1year","weight":0.2957},{"period":"ytd","weight":0.0212}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.042562},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.118335},{"month":3,"riseRate":0.5,"avgChangeRate":-0.166289},{"month":4,"riseRate":0.666667,"avgChangeRate":0.196115},{"month":5,"riseRate":0.666667,"avgChangeRate":0.024602},{"month":6,"riseRate":0.571429,"avgChangeRate":0.044863},{"month":7,"riseRate":0.714286,"avgChangeRate":0.159669},{"month":8,"riseRate":0.571429,"avgChangeRate":0.085263},{"month":9,"riseRate":0.571429,"avgChangeRate":0.012421},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.130693},{"month":11,"riseRate":0.571429,"avgChangeRate":0.153201},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.066454}],"exchange":"NASDAQ","name":"Milestone Pharmaceuticals Inc.","nameEN":"Milestone Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Milestone Pharmaceuticals Inc.(MIST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Milestone Pharmaceuticals Inc.(MIST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Milestone Pharmaceuticals Inc.,MIST,Milestone Pharmaceuticals Inc.股票,Milestone Pharmaceuticals Inc.股票老虎,Milestone Pharmaceuticals Inc.股票老虎国际,Milestone Pharmaceuticals Inc.行情,Milestone Pharmaceuticals Inc.股票行情,Milestone Pharmaceuticals Inc.股价,Milestone Pharmaceuticals Inc.股市,Milestone Pharmaceuticals Inc.股票价格,Milestone Pharmaceuticals Inc.股票交易,Milestone Pharmaceuticals Inc.股票购买,Milestone Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Milestone Pharmaceuticals Inc.(MIST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Milestone Pharmaceuticals Inc.(MIST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}